Navigation Links
Southern California Cell Company Partners With Northern California Life Science Research Technology Company for Developing Human Derived Disease Specific iPS Cell Lines
Date:6/14/2010

COSTA MESA, Calif., June 14 /PRNewswire/ -- DV Biologics LLC announced today that it has executed an agreement with System Biosciences LLC for the development of human-derived disease-specific induced pluripotent stem cell (iPSC) lines.

iPSCs are pluripotent cells which are developed from non-pluripotent cells that have undergone gene expression changes to render them pluripotent giving them the ability to then form many different cell types.

iPSCs offer an exceedingly-powerful approach to study disease biology and the need for disease-specific iPSCs is just now being fully appreciated.  For example, the California Institute of Regenerative Medicine (CIRM) recently funded a patient-specific iPSC project for producing Parkinson's Disease neurons at The Parkinson's Institute and University of Cincinnati has formed a iPSC specialized core facility to develop these cell types to study the causes of different diseases.  

DV Biologics' product portfolio offers an extensive collection of disease-specific cell types, many of which will be converted into iPSCs by System Biosciences using the company's proprietary products for reprogramming and iPSC generation.  System Biosciences offers a broad portfolio of products for stem cell research and the addition of disease-specific iPSC lines is a key component of the offering.  System Biosciences will exclusively market several iPSCs developed under this collaborative agreement to customers worldwide.

"It is DV Biologics' desire to see the products we offer incorporated into new and exciting research initiatives.  These cells will further our understanding of disease models and improve drug discovery as well as how physicians approach and administer treatments," says Francisco Silva, CEO.

Both DV Biologics and System Biosciences will be exhibiting at the International Society for Stem Cell Research (ISSCR) 8th Annual Meeting in San Francisco, California, June 16-19, 2010.  System Biosciences at exhibit booth804 and DV Biologics exhibit booth836.

About DV Biologics LLC

DV Biologics is a leading global supplier of human primary cells and cell-derived products.  DV Biologics manufactures the highest quality biological tools for use in academic institutions and pharmaceutical laboratories engaging in cell and drug based discovery and development. DV Biologics offers normal, human-derived primary cells and cell lines for research, genomic and proteomic biological tools, and a line of disease-specific primary cells and cell lines for the most accurate study of a particular disease profile.  All of DV Biologics' products are validated under the strictest quality assurance and control parameters, providing customers with reliable, guaranteed quality products for reproducible results.

DV Biologics is headquartered in Costa Mesa, California.

About System Biosciences LLC

System Biosciences (SBI) focuses on developing and commercializing innovative technologies that provide researchers with the tools to investigate and understand genomic and proteomic function. The mission of the company is to provide tools for the genome-wide analysis of the mechanisms that regulate cellular processes and biological responses.  The product and service offerings of SBI focus upon stem cell research, microRNA research, and lentiviral-based tools for life science research.

System Biosciences is headquartered in Mountain View, California.

www.dvbiologics.com

www.systembio.com


'/>"/>
SOURCE DV Biologics LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pro Medicus/Visage Imaging Signs Deal with Sydney-based Southern Radiology
2. Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture
3. Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California
4. Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession
5. Trana Discovery and Southern Research Institute Find Bioactive HIV Antiviral Compounds
6. Southern Research to Play Key Role in the Federal Governments Search for New Cancer Therapies
7. Southern Research Institute Wins $14.7 Million NIH Award to Participate in Molecular Libraries Probe Production Center Network
8. Trana Discovery and Southern Research Institute Announce the First RNA-RNA High Throughput Drug Screening Assay Platform for HIV Antivirals
9. California Patient Recruiter Sentenced to 12 Months in Prison for Medicare Fraud in Power Wheelchair Scam
10. California Natural Products Unveils CalNaturale(TM) Svelte(TM) All-Natural Sustained Energy Protein Drink
11. The California Center for Cardiothoracic Surgery Specializes in Heart Valve Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... -- Research and Markets has announced the addition ... report to their offering. ... The global orthopedic navigation system ... Increasing geriatric population prone to orthopedic diseases is a key ... the forecast period. Osteoarthritis and osteoporosis are most common disorders ...
(Date:3/29/2017)... Mar 29, 2017  Providence Medical Technology, Inc., ... addition of two industry veterans to the commercial ... the company to lead Global Marketing, and ... Mr. Lynch and Mr. Scott have over 40 ... Mr. Lynch joins the company with over 22 ...
(Date:3/29/2017)... 29, 2017  The leader in accelerated orthodontics, OrthoAccel ... Sam Daher , Manal Ibrahim , Kenji ... will be the featured microlecture presenters at the AcceleDent ... of Orthodontists (AAO) Annual Session, April 21-25, 2017. Orthodontists ... beginning daily at 11:20 a.m. On the opening morning ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , a premium medical cannabis ... the company’s executive management team with prominent executives from both inside and outside the ... Operating Officer, Ted Dumbauld , who has more than twenty years of business ...
(Date:3/29/2017)... ... March 29, 2017 , ... Immunotherapy has emerged as one of the ... is touted to be the next revolution in our fight against this complex disease. ... form of immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a ...
(Date:3/29/2017)... ... ... The Wharton School of the University of Pennsylvania is pleased to announce that ... gift to establish the Ken Moelis and Julie Taffet Moelis Advance Access Program ... for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions of business ...
(Date:3/28/2017)... Angeles, CA (PRWEB) , ... March 28, 2017 , ... ... call” asking the American public to take the Diabetes Risk Test to find out ... event, the Los Angeles World Airports will light up the evening sky by programming ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... (MRE), is pleased to be invited to the Siemens Healthineers annual customer education ... The event will take place from March 27 - 31, 2017 at ...
Breaking Medicine News(10 mins):